Status:

COMPLETED

The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

Dutch Diabetes Research Foundation

European Foundation for the Study of Diabetes

Conditions:

Type 1 Diabetes Mellitus

Hypoglycemia Unawareness

Eligibility:

All Genders

18-40 years

Phase:

NA

Brief Summary

Iatrogenic hypoglycemia is the most frequent acute complication of insulin therapy in people with type 1 diabetes (T1DM). Recurrent hypoglycemic events initiate a process of habituation, characterized...

Eligibility Criteria

Inclusion

  • Inclusion criteria for healthy subjects
  • Age: 18-40 years
  • Body-Mass Index: 18-30 kg/m2
  • Blood pressure: \<160/90 mmHg
  • Recreationally active: i.e. taking part in competitive sport or regular exercise training, of a non-professional nature, once or more a week.
  • Inclusion criteria T1DM patients with normal hypoglycemic awareness
  • Diabetes duration ≥ 1 year
  • Age: 18-40 years
  • Body-Mass Index: 18-30 kg/m2
  • HbA1c: 42-75 mmol/mol (6-9%)
  • Outcome Clarke questionnaire: 0-1
  • Blood pressure: \<160/90 mmHg
  • Recreationally active: i.e. taking part in competitive sport or regular exercise training, of a non-professional nature, once or more a week
  • Inclusion criteria T1DM patients with hypoglycemia unawareness
  • Diabetes duration ≥ 1 year
  • Age: 18-40 years
  • Body-Mass Index: 18-30 kg/m2
  • HbA1c: 42-75 mmol/mol (6-9%)
  • Outcome Clarke questionnaire: =\>3
  • Blood pressure: \<160/90 mmHg
  • Recreationally active
  • Exclusion criteria:
  • Inability to provide informed consent
  • Presence of any medical condition that might interfere with the study protocol, such as brain injuries, epilepsy, a major cardiovascular disease event or anxiety disorders
  • Use of any medication, except for oral contraceptives
  • MR(I) contraindications (pregnancy, severe claustrophobia, metal parts in body)
  • Orthopedic and/or neurological diseases that impair exercise
  • Cardiopulmonary disease as stated in the 2001 American heart association and 2002 American college of cardiology/American heart association guidelines
  • Additional exclusion criteria for all T1DM patients:
  • Use of any other medication than insulin, except for oral contraceptives or stable thyroxine supplementation therapy
  • complications of T1DM, including proliferative retinopathy, neuropathy or nephropathy

Exclusion

    Key Trial Info

    Start Date :

    January 1 2015

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2016

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT02308293

    Start Date

    January 1 2015

    End Date

    July 1 2016

    Last Update

    November 25 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Radboud umc

    Nijmegen, Netherlands